Trial Profile

A Phase 1 Study to Demonstrate the Relative Bioavailability of Fixed Dose Combinations of Ambrisentan and Tadalafil in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 28 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ambrisentan/tadalafil (Primary) ; Ambrisentan; Tadalafil
Indications Pulmonary hypertension
Focus Pharmacokinetics
Sponsors GlaxoSmithKline; GSK

Most Recent Events

03 May 2019 Results assessing bioequivalence of ambrisentan and tadalafil FDC formulation under fed and fasted states in healthy volunteers, published in the Clinical Therapeutics.
08 Aug 2017 Status changed from recruiting to completed.
04 Apr 2017 Planned number of patients changed from 60 to 106.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com